ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D. With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year.
Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, “The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems.”
To discover more about how ChemAxon's leading edge cross-platform solutions power modern cheminformatics and chemical communication, please visit http://chemaxon.us4.list-manage.com/track/click?u=367e81e89570b31a401d1b039&id=143a3390e2&e=2365cb7919 (http://chemaxon.us4.list-manage2.com/track/click?u=367e81e89570b31a401d1b039&id=b09ba37667&e=2365cb7919)
About ChemAxon
ChemAxon (http://chemaxon.us4.list-manage.com/track/click?u=367e81e89570b31a401d1b039&id=091b7a0fa5&e=2365cb7919) is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.
For further information please contact:
Alex Allardyce
ChemAxon Ltd.
+361 453 0435
aa@chemaxon.com (mailto:aa@chemaxon.com)